ICCC Q4 2018 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-6.3% YoY

Gross Profit

$1M47.5% margin

Operating Income

-$926,000-31.5% margin

Net Income

-$1M-35.8% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

+36.4%

Cash Flow

Operating Cash Flow

-$138,348

Free Cash Flow

-$237,097

Stock-Based Comp.

$86,319

Balance Sheet

Total Assets

$33M

Total Liabilities

$11M

Stockholders' Equity

$22M

Cash & Equivalents

$3M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$3M	-6.3%
Gross Profit	$1M	$1M	+15.2%
Operating Income	-$926,000	-$413,000	-124.2%
Net Income	-$1M	-$195,000	-439.5%